These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 24344034)

  • 1. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
    Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
    J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Histone deacetylase inhibits the growth and migration of human osteosarcoma cells].
    Zhang ZL; Zhang AH; Feng ZQ; An L; Zhao QH
    Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(33):2680-5. PubMed ID: 24360054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
    Zhu J; Gu J; Ma J; Xu Z; Tao H
    J BUON; 2015; 20(1):269-74. PubMed ID: 25778327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
    Duo J; Ma Y; Wang G; Han X; Zhang C
    DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
    Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
    Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
    Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
    Takai N; Kawamata N; Gui D; Said JW; Miyakawa I; Koeffler HP
    Cancer; 2004 Dec; 101(12):2760-70. PubMed ID: 15536623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.
    Nagumo T; Takaoka S; Yoshiba S; Ohashi M; Shirota T; Hatori M; Isobe T; Tachikawa T; Shintani S
    Oral Oncol; 2009 Sep; 45(9):766-70. PubMed ID: 19157955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A; Asano T; Ito K; Sumitomo M; Asano T
    BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
    Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
    Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.